Prostate-specific membrane antigen (PSMA), which is highly expressed in prostate tumours and underlies radioligand therapy, is being digitally quantified in exploratory ML-based workflows to assess expression patterns relevant to therapeutic targeting. This evidence concerns the gene FOLH1 and prostate neoplasm.